A phase II study of crisnatol mesylate in patients with ovarian carcinoma.

Abstract

Fourteen patients with advanced ovarian cancer received a 72 hour infusion of a new DNA intercalator, crisnatol mesylate, administered intravenously. There was no evidence of antitumor efficacy. A syndrome of nausea and vomiting associated with vertigo, dizziness and ataxia was observed in nearly all patients. Two of the patients developed severe CNS toxicity manifested in one by a grand-mal seizure and in the other by peripheral neuropathy. Further explorations into the potential efficacy of crisnatol mesylate administered intraperitoneally are underway.

• Authors: R V Smalley, D Goldstein, D Bulkowski, C Hannon, D Buchler, C Knudsen, R L Tuttle
• Journal: Investigational new drugs (Invest New Drugs) Vol. 10 Issue 2 Pg. 107-12 (Jul 1992) ISSN: 0167-6997 [Print] United States
• PMID: 1500264 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antigens, Tumor-Associated, Carbohydrate
• Antineoplastic Agents
• Chrysenes
• Propylene Glycols
• crisnatol

Topics

• Aged
• Aged, 80 and over
• Antigens, Tumor-Associated, Carbohydrate (drug effects)
• Antineoplastic Agents (therapeutic use)
• Carcinoma (drug therapy, immunology)
• Chrysenes (therapeutic use)
• Drug Administration Schedule
• Drug Evaluation
• Female
• Humans
• Middle Aged
• Ovarian Neoplasms (drug therapy, immunology)
• Propylene Glycols (therapeutic use)
• Treatment Outcome